BDBM476870 US10870660, Compound II-085

SMILES: Cc1ncc(CC(=O)N[C@H]2CC[C@H](CCN3CCc4nc(OCC(F)(F)F)sc4CC3)CC2)o1

InChI Key: InChIKey=OGKVKDKJRLURJP-QAQDUYKDSA-N

Data: 2 KI

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 476870   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476870 (US10870660, Compound II-085) Show SMILES Cc1ncc(CC(=O)N[C@H]2CC[C@H](CCN3CCc4nc(OCC(F)(F)F)sc4CC3)CC2)o1 |r,wU:12.12,wD:9.8,(13.24,2.65,;11.7,2.65,;10.93,1.32,;9.43,1.64,;9.27,3.17,;7.93,3.94,;6.6,3.17,;6.6,1.63,;5.27,3.94,;3.93,3.17,;2.6,3.94,;1.27,3.17,;1.27,1.63,;-.07,.86,;-1.4,1.63,;-2.74,.86,;-3.94,1.82,;-5.44,1.48,;-6.11,.09,;-7.64,-.12,;-7.91,-1.63,;-9.24,-2.4,;-10.58,-1.63,;-11.91,-2.4,;-13.24,-3.17,;-13.24,-1.63,;-11.91,-3.94,;-6.55,-2.36,;-5.44,-1.3,;-3.94,-1.64,;-2.74,-.68,;2.6,.86,;3.93,1.63,;10.67,3.8,)| Show InChI InChI=1S/C23H31F3N4O3S/c1-15-27-13-18(33-15)12-21(31)28-17-4-2-16(3-5-17)6-9-30-10-7-19-20(8-11-30)34-22(29-19)32-14-23(24,25)26/h13,16-17H,2-12,14H2,1H3,(H,28,31)/t16-,17-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0960	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020)
					More data for this Ligand-Target Pair
D(2) dopamine receptor (Homo sapiens (Human))	BDBM476870 (US10870660, Compound II-085) Show SMILES Cc1ncc(CC(=O)N[C@H]2CC[C@H](CCN3CCc4nc(OCC(F)(F)F)sc4CC3)CC2)o1 |r,wU:12.12,wD:9.8,(13.24,2.65,;11.7,2.65,;10.93,1.32,;9.43,1.64,;9.27,3.17,;7.93,3.94,;6.6,3.17,;6.6,1.63,;5.27,3.94,;3.93,3.17,;2.6,3.94,;1.27,3.17,;1.27,1.63,;-.07,.86,;-1.4,1.63,;-2.74,.86,;-3.94,1.82,;-5.44,1.48,;-6.11,.09,;-7.64,-.12,;-7.91,-1.63,;-9.24,-2.4,;-10.58,-1.63,;-11.91,-2.4,;-13.24,-3.17,;-13.24,-1.63,;-11.91,-3.94,;-6.55,-2.36,;-5.44,-1.3,;-3.94,-1.64,;-2.74,-.68,;2.6,.86,;3.93,1.63,;10.67,3.8,)| Show InChI InChI=1S/C23H31F3N4O3S/c1-15-27-13-18(33-15)12-21(31)28-17-4-2-16(3-5-17)6-9-30-10-7-19-20(8-11-30)34-22(29-19)32-14-23(24,25)26/h13,16-17H,2-12,14H2,1H3,(H,28,31)/t16-,17-	PDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	740	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020)
					More data for this Ligand-Target Pair